Apex, NC, United States of America

Melanie Beebe

USPTO Granted Patents = 1 

 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Melanie Beebe

Introduction

Melanie Beebe is a notable inventor based in Apex, North Carolina. She has made significant contributions to the field of cancer research through her innovative work on HLA-DR binding peptides. Her research focuses on developing immunogenic peptides that can be utilized in cancer vaccines, particularly targeting ovarian and breast cancer.

Latest Patents

Melanie Beebe holds 1 patent for her invention titled "HLA-DR binding peptides and their uses." This patent provides a detailed description of HLA-DR binding peptides derived from various cancer-associated antigens, including Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The peptides developed through her research have the potential to enhance cancer vaccine efficacy.

Career Highlights

Throughout her career, Melanie has worked with esteemed institutions such as the Mayo Foundation for Medical Education and Research and the University of Washington. Her dedication to advancing cancer treatment through innovative research has positioned her as a key figure in the scientific community.

Collaborations

Melanie Beebe has collaborated with prominent researchers, including Keith L. Knutson and Mary L. Disis. These partnerships have further enriched her research and contributed to the development of effective cancer therapies.

Conclusion

Melanie Beebe's work exemplifies the impact of innovation in the field of cancer research. Her contributions through patents and collaborations highlight her commitment to improving cancer treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…